Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2
Jianhua Chen, Qing Liao, Sha Yang, Jiaojiao Bian, Xianfu Li, Lu Zhao, Dan Wen, Dazhang Bai, Chunlei Yu, Chunyang Zhou, Zhengmin Xu · 2025
Read Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2 by Jianhua Chen, Qing Liao, Sha Yang, Jiaojiao Bian, Xianfu Li, Lu Zhao, Dan Wen, Dazhang Bai, Chunlei Yu, Chunyang Zhou, Zhengmin Xu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12707127.txt.
Description
Jianhua Chen and co-authors test a plant compound against a stubborn lymphoma in a 2025 study. Double-expression lymphoma grows fast because it overproduces two drivers at once, and it answers poorly to standard chemo mixes. Alantolactone, a natural compound, had shown anticancer hints, so the team checked it in cells and in mice carrying the tumors.
The compound slowed tumor growth in the mice with little harm to normal tissue. Two direct targets emerged: it steadied a kinase in its active form, which sped destruction of a growth signal, and it gripped the BCL2 protein, opening both cell-death routes. Binding scores and heat-shift tests backed the grip. The authors propose the dual hit as a treatment lead.
Catalog record
| CREATOR | Jianhua Chen, Qing Liao, Sha Yang, Jiaojiao Bian, Xianfu Li, Lu Zhao, Dan Wen, Dazhang Bai, Chunlei Yu, Chunyang Zhou, Zhengmin Xu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |